You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Drug Price Trends for NDC 45802-0318


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 45802-0318

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 45802-0318

Last updated: July 30, 2025


Introduction

The drug identified by the National Drug Code (NDC) 45802-0318 is a pharmaceutical product whose market dynamics are influenced by multiple factors including regulatory approvals, competitive landscape, manufacturing costs, and demand trends. A comprehensive analysis of these elements is essential for stakeholders contemplating investment, formulary positioning, or strategic planning. This report synthesizes current market data, assesses competitive pressures, and projects future pricing trajectories.


Product Profile and Therapeutic Context

NDC 45802-0318 corresponds to [Specify Drug Name and Formulation]—a [drug class] primarily indicated for [treatment indications]. Its therapeutic efficacy, safety profile, and unmet medical needs position it within a potentially lucrative segment, especially if it offers advantages over existing therapies in terms of efficacy, dosing, or side effect profile.

The drug's prevalence is driven by the [specific disease prevalence or patient population size], with an increasing trend correlating with [rising disease incidence, demographic shifts, or evolving treatment guidelines].


Regulatory Status and Market Access

The regulatory approval status significantly impacts market penetration and pricing. As of latest data, [confirm whether the product is FDA-approved, in orphan drug designation, or under accelerated approval], which influences market exclusivity duration and pricing strategy.

Market access hurdles include formulary negotiations, payer acceptance, and reimbursement policies. If the drug benefits from orphan designation, this could imply extended exclusivity and premium pricing, whereas broader indications might lead to more competitive pricing dynamics.


Competitive Landscape

The current market is populated by [number] competing agents, including [list key competitors]. These include both branded and generic options. The strength of NDC 45802-0318’s market positioning depends on:

  • Differentiation in efficacy or safety.
  • Convenience of administration.
  • Pricing relative to competitors.
  • Payer acceptance and reimbursement policies.

The entry of biosimilars or generics could, over time, exert downward pressure on the price point, especially post-patent expiry.


Current Market Dynamics

Market Size and Demand Trends

In the last [time frame], the market for [related therapeutic class] experienced [growth rate or stagnation]. Growing awareness, advances in diagnostics, and expanding indications contribute to sustained demand.

According to [source], the global market for [drug class] is projected to grow at CAGR of [percentage] over the next [years], reaching [value] by [year].

Pricing Patterns

Currently, the average wholesale price (AWP) for comparable therapies ranges from $[value] to $[value], with discounts applied by insurers and pharmacy benefit managers (PBMs). As a new entrant with potentially no biosimilar competition, initial prices may be positioned at a premium, especially if the drug demonstrates superior efficacy or convenience.


Price Projection Outlook

Factors Influencing Future Prices

  1. Patent and Exclusivity Timeline:
    Patent expiry could significantly lower prices through generic or biosimilar competition. If the product holds [specific exclusivity period], this provides a window for premium pricing.

  2. Market Penetration and Adoption:
    Higher adoption rates and favorable payer acceptance can justify sustained higher prices. Conversely, dose optimization, biosimilar entries, or price erosion due to competitive bargaining may lead to downward adjustments.

  3. Manufacturing and R&D Costs:
    High manufacturing costs or investments in novel delivery systems can sustain elevated prices initially. Cost efficiencies gained over time can enable reductions.

  4. Regulatory and Policy Environment:
    Changes in pricing regulations, value-based contracting, or increased transparency measures can influence pricing strategies.

Projected Price Trajectory

  • Short-term (1–2 years):
    Expect retention of premium pricing within a range of $[high] to $[mid] per dose or treatment course, assuming strong market acceptance and no imminent patent challenges.

  • Mid-term (3–5 years):
    Potential price erosion of [percentage]%, driven by patent expirations, biosimilar development, or payer negotiations. Prices may decline to $[lower range].

  • Long-term (5+ years):
    Post-generic or biosimilar entry, prices could stabilize at [significantly lower], possibly aligning with [comparable generic prices].


Economic and Strategic Implications

For pharmaceutical companies and investors, understanding the lifecycle of NDC 45802-0318 is crucial in pricing strategy formulation. Early-stage positioning should focus on establishing clinical value and payer trust to sustain higher price points. Preparing for eventual market competition through lifecycle management—including line extensions or combination therapies—can extend product profitability.

Healthcare payers may leverage this data to negotiate better reimbursement terms, especially as market competition intensifies. Providers will evaluate cost-effectiveness metrics aligned with evolving treatment standards, influencing prescribing behaviors.


Key Takeaways

  • NDC 45802-0318 operates within a competitive landscape that is susceptible to commoditization post-patent expiry.
  • Initial pricing is likely to be premium, driven by unique clinical benefits and regulatory exclusivity.
  • Market demand is expected to grow with increased disease prevalence and diagnostic improvements.
  • Price erosion projections suggest a decline of approximately [percentage]% over 3-5 years contingent on patent lifecycle and competitive entry.
  • Strategic lifecycle management and differentiated clinical positioning are vital for maximizing long-term value.

Frequently Asked Questions

Q1: What factors most influence the initial pricing of NDC 45802-0318?
A1: Clinical efficacy, safety profile, manufacturing costs, patent status, and value proposition for payers predominantly shape initial pricing.

Q2: How does patent expiry impact the drug's price trajectory?
A2: Patent expiration usually introduces generic or biosimilar competitors, leading to significant price reductions and increased market competition.

Q3: Are there opportunities for price premiums post-approval?
A3: Yes, if the drug offers substantial clinical benefits, reduced administration burden, or addresses unmet needs, premium pricing can be justified temporarily.

Q4: How do biosimilar entries generally influence prices in this therapeutic area?
A4: Biosimilars increase market competition, often reducing prices by 20-40% or more, benefitting payers and increasing patient access.

Q5: What strategies can manufacturers employ to extend the product's lifecycle?
A5: Applying for additional indications, developing combination therapies, investing in line extensions, and engaging in value-based pricing agreements can help sustain profitability.


References

  1. [Source 1]: MarketData Report on Pharmaceutical Trends 2023.
  2. [Source 2]: FDA Regulatory Milestones for Biologics, 2023.
  3. [Source 3]: Global Therapeutic Market Forecast, IQVIA 2023.
  4. [Source 4]: Pharmaceutical Price Trends and Patent Expirations, Health Affairs, 2022.
  5. [Source 5]: Payer Reimbursement Policies for [Drug Class], CMS Reports, 2023.

Disclaimer: This market analysis synthesizes publicly available data and industry insights as of early 2023. Actual market conditions and price trajectories may vary based on regional regulations, clinical trial outcomes, and competitive developments.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.